RDEA594: Phase Ib data

The open-label Phase Ib Study 111 trial in 21 gout patients showed that all patients treated with 400 and 600 mg RDEA594 plus febuxostat achieved target serum urate of <6 mg/dL vs. 67% for 40 mg febux...